Measuring the health benefits and costs of antimicrobial-resistant gonorrhea surveillance in the United States: an agent-based model and cost-effectiveness analysis.

PubMed 2026-10-01 added 2026-07-24

Ekanayake-Weber MS, Rönn MM, Yin X, Hsu K, Li Y, Gift TL, Chesson H, Frankson R, Salomon JA, Grad YH, Yaesoubi R